Earnings Ahead

REGN - Regeneron Pharmaceuticals

716.09 -68.29 -8.71

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

About

Profile

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.


Headquarters

Tarrytown, New York, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

REGN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Regeneron stock dips amid decline in Eylea sales despite Q1 beat
  • Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M
  • Regeneron looks to strong Dupixent, Eylea sales in Q1 report
  • Regeneron Pharmaceuticals Q1 2023 Earnings Preview
  • Sanofi Q1 profit climbs on Dupixent as drug on track for €10B this year
  • Democratic senators introduce bill to enhance CMS drug price negotiations
  • Ghana 1st in world to approve new malaria vaccine by Oxford
  • U.S. launches $5B program to speed up development of next-gen COVID vaccines
  • Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M
  • Regeneron Libtayo gets expanded approval in EU for lung cancer subtype
  • Amgen, AstraZeneca's asthma therapy Tezspire gets UK's NICE backing
  • Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs
  • Supreme Court hears arguments in Amgen Repatha patent case against Sanofi
  • Regeneron draws more bullish views from analysts after Dupixent COPD data
  • Regeneron up 7% following Dupixent data, Raymond James upgrade
  • Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals
  • Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids
  • Sanofi and Regeneron's Dupixent gets approval in EU to treat eczema in kids over 6 months
  • Easing COVID pandemic sees many pharmas seeking alternate revenue streams
  • FDA accepts for review Regeneron/Sanofi's Dupixent application for inflammatory skin condition
Date Price Open High Low Vol Change
Jan 29 687.27 685.96
697.57
682.33
523K 0.14%
Jan 28 686.33 682.11
690.3
678.13
640K 0.24%
Jan 27 684.71 676.73
698.45
676.73
1.1M 1.32%
Jan 24 675.79 688.74
693.84
675.11
1.0M -2.71%
Jan 23 694.64 680.54
696.19
678.28
1.1M 2.15%
 
Jan 22 680.03 689.77
699.88
677.68
945K -1.13%
Jan 21 687.8 687.46
692.93
681.52
1.1M 0.91%
Jan 17 681.58 705.34
707.48
680.89
1.1M -1.68%
Jan 16 693.23 701.04
706.54
691.33
854K -1.45%
Jan 15 703.43 700.61
712.6
698.2
880K 1.82%
Jan 14 690.87 714.01
715.98
686
792K -3.63%
Jan 13 716.9 669.24
717.37
666.25
1.4M 2.87%
Jan 10 696.88 721.33
724.73
691
1.1M -5%
Jan 8 733.59 728.04
743.28
725.6
759K 0.45%
Jan 7 730.3 716.34
734.44
716.34
803K 1.96%
Jan 6 716.26 715
733.69
713.75
820K -0.26%
Jan 3 718.15 716.07
722
714.76
558K 0.41%
Jan 2 715.19 720.86
726.81
711.92
479K 0.40%
Dec 31, 2024 712.33 703.9
713
703.39
474K 1.39%
Dec 30, 2024 702.59 708.04
708.97
700.42
537K -1.38%
Dec 27, 2024 712.4 710.52
718.99
709.09
796K -0.6%
Dec 26, 2024 716.68 709.08
718.49
709.08
619K 0.31%
Dec 24, 2024 714.47 712.3
720
706.15
382K -0.09%
Dec 23, 2024 715.13 708.38
718.19
706.16
867K 1.89%
Dec 20, 2024 701.85 710.2
717.61
700.83
1.9M -0.9%
Dec 19, 2024 708.25 711
714.05
693
1.1M -0.89%
Dec 18, 2024 714.62 735.21
745
712.3
908K -3.43%
Dec 17, 2024 740.01 721.37
744.8
721.08
979K 2.09%
Dec 16, 2024 724.87 730.52
739.39
722.23
920K -0.88%
Dec 13, 2024 731.3 738.45
740.17
728.68
697K -1.31%
Dec 12, 2024 740.97 773.12
778.73
740.46
924K -4.14%
Dec 11, 2024 773 778.15
781.32
766.86
777K -0.71%
Dec 10, 2024 778.5 784.1
791.49
762.7
1.3M -1.21%
Dec 9, 2024 788 777
800.99
773
1.0M 1.29%
Dec 6, 2024 778 768.64
778.12
765.16
814K 1.32%
Dec 5, 2024 767.9 751.55
768.02
749.68
779K 1.81%
Dec 4, 2024 754.26 748.56
756.13
744.14
732K 0.63%
Dec 3, 2024 749.57 758.53
770
747.57
650K -1.68%
Dec 2, 2024 762.34 750.01
763.89
748.41
896K 1.62%
Nov 29, 2024 750.22 746.62
754.51
740
490K -0.62%
Nov 27, 2024 754.87 756.72
762.16
749.52
545K 0.24%
Nov 26, 2024 753.03 743.19
754.18
736.5
780K 0.47%
Nov 25, 2024 749.51 747.97
757.86
741.62
1.2M 1.56%
Nov 22, 2024 738 744.7
751.4
737.63
1.0M -0.87%
Nov 21, 2024 744.5 744.87
757.55
735.95
973K 0.15%
Nov 20, 2024 743.35 742.19
750.69
736.01
655K -0.17%
Nov 19, 2024 744.6 756.56
758.6
736.19
980K -2.28%
Nov 18, 2024 762 751.97
762.7
750.2
1.0M 0.69%
Nov 15, 2024 756.81 782.78
783.1
753.69
1.4M -3.28%
Nov 14, 2024 782.51 800.15
803.41
780.95
1.1M -2.71%
Nov 13, 2024 804.33 815.45
823.56
803.33
590K -2.03%
Nov 12, 2024 821 824.31
831
817.14
678K -0.57%
Nov 11, 2024 825.68 824
834.42
820.45
692K -0.33%
Nov 8, 2024 828.42 826.57
830.73
822.8
564K 0.48%
Nov 7, 2024 824.48 817.88
832.53
814.05
781K 0.96%
Nov 6, 2024 816.65 844.51
844.51
813.53
880K -1.54%
Nov 5, 2024 829.43 824.94
836.63
819.14
633K 0.07%
Nov 4, 2024 828.84 845.59
852.01
826.76
744K -1.75%
Nov 1, 2024 843.6 844.61
862
837.88
1.1M 0.64%
Oct 31, 2024 838.2 875
883.15
815.99
2.3M 0%